SCHEMBL279579

SCHEMBL279579

Cc1cccc(C(=O)N2CC(C)CC(C)C2)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.62
HTT P42858 1/20 0.62
PLA2G1B P04054 1/20 0.61
ATG4B Q9Y4P1 1/20 0.61
HPGD P15428 2/20 0.60
GAA P10253 1/20 0.58
HSD17B10 Q99714 1/20 0.56
ALDH1A1 P00352 1/20 0.52
CACNA1H O95180 1/20 0.51
HSD11B1 P28845 1/20 0.50
GABRD O14764 1/20 0.50
GABRA1 P14867 1/20 0.50
GABRB1 P18505 1/20 0.50
GABRA5 P31644 1/20 0.50
GABRA3 P34903 1/20 0.50
GABRA2 P47869 1/20 0.50
GABRB2 P47870 1/20 0.50
GABRA4 P48169 1/20 0.50
MGLL Q99685 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10329768 0.94 HTT (0.65) L3MBTL1HTTPLA2G1BATG4BHPGD
SCHEMBL10724012 0.90 PLA2G1B (0.69) L3MBTL1HTTPLA2G1BATG4BHPGD
SCHEMBL22461737 0.85 HTT (0.67) L3MBTL1HTTHPGDALDH1A1HSD11B1
SCHEMBL2667154 0.84 HPGD (0.64) L3MBTL1HTTHPGDHSD17B10ALDH1A1
SCHEMBL280087 0.84 HPGD (0.64) L3MBTL1HTTHPGDHSD17B10ALDH1A1
SCHEMBL3455949 0.83 PLA2G1B (0.60) L3MBTL1HTTPLA2G1BATG4BHPGD
SCHEMBL2633022 0.83 HPGD (0.62) L3MBTL1HTTHPGDHSD17B10HSD11B1
SCHEMBL18377751 0.83 HPGD (0.62) L3MBTL1HTTHPGDHSD17B10ALDH1A1
SCHEMBL8053380 0.82 HPGD (0.67) L3MBTL1HTTHPGDALDH1A1
SCHEMBL14236778 0.82 PLA2G1B (0.87) PLA2G1BATG4BHPGDGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206125-B2 Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2015-12-08 US disclosed
US-9206125-B2 Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2015-12-08 US disclosed
US-9206125-B2 Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2015-12-08 US disclosed
US-20130203738-A1 USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) NAGOYA CITY UNIVERSITY (JP) 2013-08-08 US disclosed
US-20130203738-A1 USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) NAGOYA CITY UNIVERSITY (JP) 2013-08-08 US disclosed
US-20130203738-A1 USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) NAGOYA CITY UNIVERSITY (JP) 2013-08-08 US disclosed
EP-2535059-A1 USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) Public University Corporation Yokohama City University (JP) 2012-12-19 EP disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203738-A1 USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) RCOR1, MSI2, RCOR3 L3MBTL1 733/4885HTT 251/4885PLA2G1B 4678/4885
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL L3MBTL1 676/4885HTT 1630/4885PLA2G1B 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.